Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986504 in Recurrent Glioblastoma With MTAP Deleted Tumors
NCT06883747Phase 1Recruiting
- Sponsor
- Ivy Brain Tumor Center
- Start
- Apr 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MRTX1719 in glioblastoma (GBM), sponsored by Ivy Brain Tumor Center. Primary endpoints: BMS-986504 Concentration in Tumor Tissue, Number of Treatment-Emergent Adverse Events up to 15 months and 4 more. Started Apr 2025; status: recruiting.
02
Drugs
MRTX1719
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06883747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06883747.